Table 1.
Demographics and clinical features of study population.
| Study population (n = 413) | AIH unvaccinated (n = 258) | AIH vaccinated (n = 155) | |
|---|---|---|---|
| Median age, years (range) | 52 (17–85) | 50 (17–85) | 53 (18–83) |
| Female, n (%) | 333 (80.6) | 205 (79.5) | 128 (82.6) |
| Variant syndromes (PBC/PSC), n (%) | 39 (9.4) | 26 (10.1) | 13 (8.4) |
| Cirrhosis, n (%) | 117 (28.3) | 71 (27.5) | 46 (29.7) |
| Smoking (current), n (%) | 27 (6.5) | 15 (5.8) | 12 (7.7) |
| Alcohol, n (%) | 5 (1.2) | 4 (1.6) | 1 (0.6) |
| Co-morbidity, (%) | 180 (43.6) | 109 (42.2) | 71 (45.8) |
| Arterial Hypertension | 106 (25.7) | 63 (24.4) | 43 (27.7) |
| Diabetes mellitus | 89 (21.5) | 55 (21.3) | 34 (21.9) |
| Cardiac disease | 24 (5.9) | 13 (5) | 11 (7.1) |
| Respiratory disease | 17 (4.1) | 7 (2.8) | 10 (6.5) |
| Kidney insufficiency | 16 (3.9) | 8 (3.1) | 8 (5.2) |
| Active cancer | 7 (1.7) | 3 (1.2) | 4 (2.6) |
| AIH medications, n (%) | 388 (93.9) | 238 (92.2) | 150 (96.8) |
| AZA alone (median dose, mg) | 103 (24.9) 87.5 (25–200) |
65 (25.2) 75 (25–200) |
38 (24.5) 100 (25–200) |
| Prednisolone (equivalent) alone (median dose, mg) | 67 (16.2) 5 (2.5–60) |
49 (19.0) 5 (2.5–60) |
18 (11.6) 5 (2.5–40) |
| MMF alone (median dose, mg) | 14 (3.4) 1500 (500–2000) |
10 (3.9) 1000 (500–2000) |
4 (2.5) 2000 (500–2000) |
| Tacrolimus alone (median dose, mg) | 4 (0.9) 3 (1–7) |
3 (1.2) 3 (1.5–7) |
1 (0.6) 4 (1–6) |
| 6-MP alone | 1 (0.2) | 1 (0.4) | – |
| Methotrexate alone | 1 (0.2) | – | 1 (0.6) |
| Any combination | 198 (49.1) | 110 (42.6) | 88 (56.8) |
| Symptoms at presentation, n (%) | 384 (93) | 237 (91.9) | 147 (94.8) |
| Medical therapies for COVID-19, n (%) | 139 (33.7) | 118 (45.7) | 21 (13.5) |
| Antibiotics, n (%) | 111 (26.9) | 88 (34.1) | 23 (14.8) |
AZA, azathioprine; MMF, mycophenolate mofetil; 6-MP, mercaptopurine; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.